In order to determine the efficacy of curcumin in ameliorating symptoms of neurodegeneration in the mouse model of Niemann–Pick C1, a variety of formulations and dosages of curcumin, one comparable to one previously reported as efficacious, were provided orally to Npc1−/−mice. Plasma levels of curcumin, survival, tests of motor performance, and memory (in some cases) were performed. We found variable, but mild, increases in survival (1.5% to 18%). The greatest increased survival occurred with the highest dose (which was unformulated) while the control for the lipidated formulation (containing phosphatidylcholine and stearic acid) had an equivalent impact and other formulations, while not significantly increased, are also not statistically different in effect from the highest dose.
We conclude that curcumin is not a highly efficacious treatment for neurodegeneration in Npc1−/− mice. Phosphatidylcholine and stearic acid should be studied further.Highlights
▸ Curcumin exerts anti-Alzheimer's effect in animal models. ▸ Niemann–Pick C1 is considered as juvenile Alzheimer's. ▸ We tested curcumin's effects in Niemann–Pick C1 animal models. ▸ Four different formulations/dosages had minimal effects.